Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 20/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133165 | 0.89 | ACACB (0.38) | ACACB | |
| SCHEMBL20443701 | 0.89 | ACACB (0.41) | ACACB | |
| SCHEMBL20325865 | 0.86 | ACACB (0.39) | ACACB | |
| SCHEMBL21906682 | 0.86 | ACACB (0.36) | ACACB | |
| SCHEMBL22047351 | 0.83 | ACACB (0.41) | ACACB | |
| SCHEMBL18611814 | 0.83 | ACACB (0.41) | ACACB | |
| SCHEMBL18611812 | 0.83 | ACACB (0.41) | ACACB | |
| SCHEMBL18551308 | 0.83 | ACACB (0.40) | ACACB | |
| SCHEMBL18551220 | 0.82 | ACACB (0.34) | ACACB | |
| SCHEMBL25059246 | 0.80 | ACACB (0.34) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | PTK2, CTTN, CRBN | ACACB 2120/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | ACACB 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.